748 Phase 1/2 Study of the Hexavalent OX40 Agonist INBRX-106 Alone and in Combination with Pembrolizumab in Select Solid Tumors
Journal for ImmunoTherapy of Cancer(2023)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined